近日，上海证券交易所（上交所）对深圳亚辉龙生物科技股份有限公司（简称“亚辉龙”）发布监管警示。此次监管警示主要源于亚辉龙在信息披露方面存在不规范行为。根据上交所公告，亚辉龙在2023年年度业绩预告中未能准确、及时地反映公司实际经营状况，导致市场预期与实际情况出现较大偏差，影响了投资者的判断和市场秩序。上交所指出，上市公司应严格遵守信息披露相关规定，确保信息的真实性、准确性、完整性和及时性。此次监管警示虽不属于行政处罚，但属于交易所自律监管措施之一，旨在督促公司及相关责任人提高合规意识，完善内部治理。亚辉龙已表示将认真整改，并加强信息披露管理，以维护投资者权益和资本市场稳定。该事件再次提醒A股上市公司，信息披露不仅是法定义务，更是赢得市场信任的关键。
Recently, the Shanghai Stock Exchange (SSE) issued a regulatory warning to Shenzhen YHLO Biotech Co., Ltd. (referred to as ‘YHLO’). The warning stems primarily from irregularities in the company’s information disclosure practices. According to the SSE announcement, YHLO failed to accurately and timely reflect its actual operating performance in its 2023 annual earnings forecast, leading to a significant discrepancy between market expectations and actual results, thereby affecting investor judgment and market order. The SSE emphasized that listed companies must strictly comply with information disclosure regulations to ensure the truthfulness, accuracy, completeness, and timeliness of disclosed information. Although this regulatory warning is not an administrative penalty, it constitutes a self-regulatory measure by the exchange aimed at urging the company and its responsible personnel to enhance compliance awareness and improve internal governance. YHLO has stated it will rectify the issues seriously and strengthen its information disclosure management to protect investor interests and maintain market stability. This incident serves as another reminder to A-share listed companies that information disclosure is not only a legal obligation but also crucial for earning market trust.
原创文章，作者：admin，如若转载，请注明出处：https://ktez.cn/10457.html